Administration of Lymphodepletion

DRUG2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute

Conditions

Metastatic Melanoma

Unknown Phase

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

CompletedNCT01005745

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Melanoma

Start: 2009-10-20End: 2025-08-18Updated: 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

CompletedNCT01701674

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Melanoma

Start: 2012-10-09End: 2025-08-21Updated: 2025-12-19

Related Papers

Impact of clonal hematopoiesis on hematologic recovery and outcomes following tumor-infiltrating lymphocyte therapy

Blood2025-11-03

CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion

Journal for ImmunoTherapy of Cancer2025-04-016 citations

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

384 An investigation into the role of CD4+ tumor-infiltrating lymphocytes (TIL) in metastatic melanoma patients with a complete response to adoptive cell therapy

Regular and Young Investigator Award Abstracts2021-11-01

385 Identification and enrichment of neoantigen-reactive T cells to optimize adoptive cell transfer with tumor-infiltrating lymphocytes (TIL)

Regular and Young Investigator Award Abstracts2021-11-01

Final report of a pilot trial combining ipilimumab and adoptive cell therapy.

Journal of Clinical Oncology2017-03-012 citations